• EU nod for Vertex CF therapy Kaftrio pharmatimes
    August 24, 2020
    Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor) has been approved by the European Commission for use in combination with ivacaftor to treat people aged 12 years and older with certain forms of cystic fibrosis.
PharmaSources Customer Service